Loading...
Integrating subgroups with mixed-type endpoints in early phase oncology trials
Testing anti-cancer agents with multiple disease subtypes is challenging and it becomes more complicated when the subgroups have different types of endpoints (such as binary endpoints of tumor response and progression-free survival endpoints). When this occurs, one common approach in oncology is to...
Na minha lista:
| Udgivet i: | Stat Methods Med Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6776708/ https://ncbi.nlm.nih.gov/pubmed/30945609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0962280219840050 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|